2025 International Society of Endocrinology and Diabetes

International Academic Conference Focuses on Tirzepatide: A New Dawn in the Treatment of Obesity and Metabolic Diseases

Recently, the International Society of Endocrinology and Diabetology hosted a world-leading academic conference on endocrinology and diabetology in the United States. Over 30 countries were represented by authoritative experts, who engaged in in-depth discussions on the latest advances in metabolic disease treatment. Among them, Dr. Louis, Professor of International Endocrinology and Diabetology, served as the core academic chair, leading the discussions throughout the event. The innovative drug Tirzepatide, with its breakthrough dual-target mechanism, became the absolute focal point of the meeting.

As a leading scholar in the field of metabolic diseases, Dr. Louis described Tirzepatide in his opening keynote as “a milestone drug redefining the paradigm of obesity treatment.” He explained: “Traditional anti-obesity drugs are constrained by single-target mechanisms, often yielding only short-term weight loss or improvement of a single metabolic marker. By contrast, Tirzepatide—acting as a dual agonist of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and the Glucagon-Like Peptide-1 (GLP-1) receptors—breaks this limitation.”

Dr. Louis further detailed the drug’s mechanism: “Through the GLP-1 pathway, it slows gastric emptying and suppresses appetite, reducing calorie intake at the ‘input end.’ Simultaneously, through the GIP receptor pathway, it enhances insulin sensitivity and optimizes energy metabolism, boosting efficiency at the ‘output end.’ This ‘two-pronged approach’ enables simultaneous weight loss and metabolic improvement, redefining the therapeutic ceiling for obesity medications.”

Clinical Evidence Highlights

In the clinical results session, Dr. Louis highlighted several international multi-center trials led by top U.S. pharmaceutical companies and research institutions.

• SURMOUNT-1 Trial (sponsored by Eli Lilly, USA): A 72-week follow-up showed that non-diabetic overweight/obese patients treated with 15 mg of Tirzepatide achieved an average body weight reduction of 22.5% (~24 kg), compared to 2.4% in the placebo group—nearly 10 times greater. Notably, 63% of patients in the treatment arm achieved ≥20% weight loss versus just 1.3% in the placebo group. “This not only validates Tirzepatide’s powerful weight-loss effect but also underscores its potential in long-term weight management,” Dr. Louis emphasized. “For obese patients with hypertension, hyperlipidemia, and other metabolic issues, this means the possibility of one-stop improvement of multiple health risks.”

• Cardiovascular Disease (SUMMIT Trial, AHA 2024): In obese patients with heart failure with preserved ejection fraction (HFpEF), Tirzepatide reduced the composite endpoint of cardiovascular death or worsening heart failure by 38%. Patients also reported higher quality of life scores (KCCQ-CSS +6.9 vs placebo), an average 11.9% greater reduction in BMI, and a +18.3 m improvement in the 6-minute walk test. Dr. Louis remarked that this highlights Tirzepatide’s cardiovascular protective potential, offering new hope for patients with obesity and heart disease.

• Type 2 Diabetes (SURPASS series): Tirzepatide, as monotherapy or in combination, significantly reduced HbA1c levels by up to 2.4%, helping many patients achieve glycemic control. In a 176-week Phase III study in overweight/obese individuals with prediabetes, it reduced progression to type 2 diabetes by 94%.

• Non-Alcoholic Steatohepatitis (NASH): Phase II trials showed Tirzepatide significantly improved hepatic steatosis, inflammation, and fibrosis markers.

• Obstructive Sleep Apnea (SURMOUNT-OSA): Treatment markedly reduced apnea-hypopnea events. In the highest dose group, 43.0%–51.5% of patients achieved remission criteria, with severity reduced by 62.8% (~30 fewer events per hour).

• Arthritis (Mayo Clinic 2024): In obese patients with rheumatoid arthritis, after 24 weeks, disease activity score (DAS28-ESR) dropped by 1.2 points, joint pain/swelling decreased by 35%, and inflammatory cytokines (TNF-α, IL-6) fell by 28%–32%. Researchers concluded Tirzepatide provides dual “metabolic regulation + anti-inflammatory” benefits, with multiple Phase III trials ongoing.

• Cancer Prevention: An American Cancer Society cohort study (120,000 obese individuals) reported long-term Tirzepatide use reduced endometrial cancer risk by 41% and estrogen receptor–positive breast cancer risk by 29%. Johns Hopkins basic research further suggested Tirzepatide inhibits mTOR signaling, reduces tumor-promoting adipokines, and enhances immune recognition of cancer cells. These findings are now part of NIH-funded translational research.

• Mental Health (Stanford University, 2024): In 200 obese patients with mild-to-moderate depression, 16 weeks of Tirzepatide lowered PHQ-9 scores by 4.8 points; 58% achieved symptom remission (vs. 23% with placebo). Cerebrospinal fluid serotonin rose 22%, prefrontal cortex metabolism increased 18%, aligning with patient reports of improved mood and energy. Dr. Louis commented: “The mental health improvements reflect a ‘metabolism-neuro-emotion’ axis synergy, offering a new pathway for obese patients with mood disorders.”

Formulation Innovation & Safety

In expert discussions, Dr. Louis emphasized Tirzepatide’s safety and formulation advances. The current injection form shows a favorable profile, with mostly mild-to-moderate gastrointestinal effects (diarrhea, nausea) occurring 15%–20% more often than placebo, usually early in treatment, with <5% discontinuation.

Of greater note, ongoing Phase III trials of oral Tirzepatide (using enteric coatings and absorption enhancers) demonstrate equivalent efficacy, 60% lower GI adverse events, and no new safety concerns—dramatically improving adherence.

This breakthrough aligns with the already FDA-approved EQVP® GLP-1 RA Potent 9-in-1 Lozenge, an oral formulation developed by leading obesity management experts. By combining Tirzepatide with natural herbal components, EQVP® Lozenge delivers powerful metabolic regulation and fat burning while minimizing GI irritation—making it a more patient-friendly option for those avoiding injections and requiring long-term therapy. Together, these advances represent a new trend in “high-efficacy, low-burden” obesity treatment.

Looking Ahead

On questions of long-term safety and dose optimization across populations, Dr. Louis noted: “The next step is long-term real-world studies, planned with the CDC and EASD, to refine treatment guidelines. We also need to explore combined regimens with metabolic surgery and lifestyle interventions to enhance precision.”

In closing, Dr. Louis reiterated Tirzepatide’s disruptive significance: “From mechanism innovation to formulation breakthroughs, from weight loss to multi-system benefits, Tirzepatide has surpassed the limits of traditional drugs. Its dual-target advantage solves the core pain points of ‘unsustained weight loss and limited metabolic improvement,’ and aligns with the future of multi-target, multi-dimensional therapies for metabolic diseases. With global prevalence still rising, I firmly believe that in the next decade, dual-target agonists like Tirzepatide will dominate the field, delivering more effective, comprehensive, and convenient treatment options for hundreds of millions worldwide.”

This conference not only underscored Tirzepatide’s transformative role but also, through Dr. Louis’s authoritative insights, provided strong academic support for its clinical adoption and ongoing research.